Results

Total Results: 2,078 records

Showing results for "drugs".

401. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/evidence-based-treatment-for-pressure-ulcers-by-stage
     September 22, 2010 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

402. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/i-would-like-to-suggest-a-study-in-effective-treatment-of-tinnitus-and-vertigo
     February 17, 2012 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

403. What is the comparative effectiveness of imaging techniques for the assessment of response to treatment in metastatic breast cancer? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-is-the-comparative-effectiveness-of-imaging-techniques-for-the-assessment-of-response-to-treatment-in-metastatic-breast-cancer
     December 28, 2011 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

404. Can screening among the general adult male population for elevated PCA3 (also known as DD3) gene expression, to identify those at risk for prostate cancer who may be candidates for prostate biopsy, reduce morbidity and mortality? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/can-screening-among-the-general-adult-male-population-for-elevated-pca3-also-known-as-dd3-gene-expression-to-identify-those-at-risk-for-prostate-cancer-who-may-be-candidates-for-prostate-biopsy-reduce-morbidity-and-mortality
     July 29, 2010 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to

405. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - Given the extensive detail on harms for these drugs, we were unable to summarize in a row and have … rather than redoing the entire meta-analysis, we chose to do focused meta- analyses just on those drugs … discussion: “In addition, larger, higher-quality studies have almost all been conducted with new drugs … with pharmaceutical company funding, and these were the only drugs with moderate strength of evidence … treatments improved quality of life, studies were short-term with unclear risk of bias, all oral drugs

406. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - Given the extensive detail on harms for these drugs, we were unable to summarize in a row and have … rather than redoing the entire meta-analysis, we chose to do focused meta- analyses just on those drugs … discussion: “In addition, larger, higher-quality studies have almost all been conducted with new drugs … with pharmaceutical company funding, and these were the only drugs with moderate strength of evidence … treatments improved quality of life, studies were short-term with unclear risk of bias, all oral drugs

407. Comparative Effectiveness of Drug Therapy for Psoriatic Arthritis in Adults – An Update to the 2007 Report | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/arthritis-psoriatric/research-protocol
     December 06, 2010 - Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs (DMARDs … Finally, very little is known about the benefits or risks of these drugs in different patient subgroups … Golimumab Simponi® Tocililizumab Actemra®, RoActemrai® Comparators: All key questions: all review drugs

408. Comparative Effectiveness Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Pharmacokinetics, Indications and Dosing of Included Drugs Drug and Trade Name (Trade names … provided only for drugs under patent.) … incapaciation and definite hazard to patient's health; adverse events defined according to Compendium of Pharmaceuticals … having a therapeutic effecton the knee joint) no yes Dolorgiet Pharmaceuticals (Germany … Pharmacokinetics, Indications and Dosing of Included Drugs Appendix B.

409. Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/multiple-sclerosis/research-protocol
     December 17, 2013 - Thus, major questions of interest are whether or not disease-modifying MS drugs alter the natural history … evidence for patient values, beliefs, and preferences regarding discontinuation of disease-modifying drugs … KQ2 : What are individual values, beliefs, and preferences regarding discontinuing disease-modifying drugs … Since these drugs are intended for long-term use, possibly for decades, we are looking for studies that … FDA-approved disease modifying drugs were only available after 1993.

410. MS Protocol draft_12_12-13 clean[2] (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/multiple-sclerosis_research-protocol.pdf
     December 17, 2013 - Thus, major questions of interest are whether or not disease-modifying MS drugs alter the natural history … evidence for patient values, beliefs, and preferences regarding discontinuation of disease- modifying drugs … KQ2: What are individual values, beliefs, and preferences regarding discontinuing disease-modifying drugs … Since these drugs are intended for long-term use, possibly for decades, we are looking for studies that … FDA-approved disease modifying drugs were only available after 1993.

411. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - health care sector, horizon scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results The table below lists the five topics for which (1) preliminary phase III data for drugs, at … San Diego (CA): Amylin Pharmaceuticals, Inc.; 2012 Jan 27 [accessed 2014 Apr 10]. [5 p]. … Med Lett Drugs Ther. 2013 Dec 9;55(1431):97-8. PMID: 24322663. 74. … Drugs. 2013 Feb;73(2):187-93. PMID: 23335133.

412. pneumonia-antibiotic-treatment-protocol-130718 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/pneumonia-antibiotic-treatment_research-protocol.pdf
     July 19, 2013 - significantly for patients with HAP.3-6 Optimal treatment involves choosing the right drug or combination of drugs … For drugs with a narrow therapeutic index, such as vancomycin and the aminoglycosides, the risk of toxicities … also reduce nephrotoxicity in patients who are receiving aggressive dosing, concurrent nephrotoxic drugs … discussion, a new KQ was added to examine the effect of using prolonged or continuous infusions of drugs … creatinine clearance, time above MIC, and ratio of AUC to MIC (see Table 1 below for drug classes and drugs

413. Comparative Effectiveness Review No. 234 Evidence Summary: Management of Primary Headaches in Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-234-headaches-pregnancy-summary.pdf
     November 01, 2020 - Given the heightened sensitivity about the potential impact of drugs on the fetus or infant, there is … Treatment—triptans, ergot products, nonsteroidal anti-inflammatory drugs (NSAIDs: naproxen), and antihistamines

414. Comparative Effectiveness Review No. 234 Evidence Summary: Management of Primary Headaches in Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-234-headaches-pregnancy-summary.pdf
     November 01, 2020 - Given the heightened sensitivity about the potential impact of drugs on the fetus or infant, there is … Treatment—triptans, ergot products, nonsteroidal anti-inflammatory drugs (NSAIDs: naproxen), and antihistamines

415. Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/rheumatoid-arthritis-2007/research
     November 19, 2007 - Current Page Topic Timeline Jan. 1, 2005 Topic Initiated Nov. 19, 2007 Systematic Review Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults Systematic Review Archived November 19, 2007 Web Version [NLM Site] Download Main Document PDF 787.7 KB Related…

416. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
     September 29, 2014 - decade ago the FDA established a 12-week duration of observation as a requirement for approval of drugs … behavior in persons with a legitimate (if not always appropriate) need to use the opioid class of drugs … opioid drug abuse and misuse, while simultaneously enabling appropriate access to pain-relieving drugs … Without considering how opioids should be used in the context of other drugs, devices or techniques, … in its class. ii Methadone’s unique properties distinguish it from other opioid drugs.

417. Renal Artery Stenosis Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/renal-update/research-protocol
     January 20, 2015 - The antihypertensive agents, lipid-lowering drugs, and antiplatelet agents are all FDA approved for hypertension … The risks and adverse events of the drugs are well-understood and include symptomatic hypotension, myalgia … therapy, including “aggressive medical therapy” (antihypertensive, antiplatelet, and lipid-lowering drugs … Categorical (eg, better/worse) Continuous BP Medication need (eg, number of antihypertensive drugs

418. Effectiveness of Screening and Treatment of Subclinical Hypothyroidism or Hyperthyroidism | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/hypothyroidism-hyperthyroidism-screening-treatment/research-protocol
     March 10, 2010 - disease, family history of thyroid disease, atrial fibrillation, and ingestion of iodine-containing drugs … Treatment of hyperthyroidism includes antithyroid drugs and radioactive iodine treatment. … Generic Name: Levothyroxine sodium (Brand Name: Levo-T, Synthroid, Levothroid, Levoxyl, Unithroid); All drugs … overdosage could result in a decrease in bone density Harms of antithyroid agents: Antithyroid Drugs

419. S143 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s143.pdf
     October 01, 2007 - Key Words: cohort studies, propensity scores, observational research (Med Care 2007;45: S143–S148) Drugs … Statins inhibit endogenous cholesterol synthesis, and ther- apy with these drugs improves lipoprotein … including ambulatory care, approved specialists and outside referrals, laboratory work, and prescription drugs

420. Ch 8-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_8-user-guide-to-ocer_130129.pdf
     October 01, 2013 - claims data Information EHRs Administrative Claims Prescriptions ordered Yes No Pharmacy data (drugs … The NDC is a unique, 10-digit, 3-segment number that is a standard product identifier for human drugs … Claims submitted to insurance companies for payment for drugs are submitted with the NDC code as well … The researchers identified differential adherence to antihypertensive drugs, which has implications … Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly